The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on ...

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

Acquires a highly selective and brain penetrant NLRP3 inhibitor from Mwyngil Therapeutics Company's lead candidate BT-267, a ...

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. Amgen (NASDAQ: AMGN) ...

Investing.com -- Painreform Ltd (NASDAQ: PRFX) stock fell 11% following the company’s announcement of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company ...

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

API Innovation Center, founded in 2021, aims to secure domestic drug production. It's developing six molecules and expanding ...

The first phase of Fujifilm Biotechnologies’ $3.2-billion large-scale cell culture biopharmaceutical manufacturing plant in North Carolina is scheduled to begin operating this year.